Platelet CD40 Exacerbates Atherosclerosis by Transcellular Activation of Endothelial Cells and Leukocytes

被引:101
作者
Gerdes, Norbert [1 ]
Seijkens, Tom [2 ]
Lievens, Dirk [1 ]
Kuijpers, Marijke J. E. [3 ]
Winkels, Holger [1 ]
Projahn, Delia [1 ]
Hartwig, Helene [2 ]
Beckers, Linda [2 ,4 ]
Megens, Remco T. A. [1 ]
Boon, Louis
Noelle, Randolph J. [5 ]
Soehnlein, Oliver [1 ,2 ]
Heemskerk, Johan W. M. [3 ]
Weber, Christian [1 ,3 ]
Lutgens, Esther [1 ,2 ]
机构
[1] Univ Munich, Inst Cardiovasc Prevent IPEK, Munich, Germany
[2] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[3] Maastricht Univ, Dept Biochem, Cardiovasc Res Inst Maastricht CARIM, NL-6200 MD Maastricht, Netherlands
[4] Bioceros BV, Utrecht, Netherlands
[5] Norris Cotton Canc Ctr, Dept Microbiol & Immunol, Geisel Sch Med Dartmouth, Lebanon, NH USA
关键词
atherosclerosis; CD40; ligand; leukocytes; blood platelets; immune system; ACUTE CORONARY SYNDROMES; ACUTE MYOCARDIAL-INFARCTION; MONOCLONAL-ANTIBODY; SOLUBLE CD40L; UP-REGULATION; LIGAND CD154; IN-VIVO; DISEASE; MICE; RISK;
D O I
10.1161/ATVBAHA.115.307074
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective- Beyond their eminent role in hemostasis and thrombosis, platelets are recognized as mediators of inflammation. Platelet cluster of differentiation 40 (CD40) ligand (CD40L and CD154) plays a key role in mediating platelet-induced inflammation in atherosclerosis. CD40, the receptor for CD40L, is present on platelets; however, the role of CD40 on this cell type is until now undefined. Approach and Results- We found that in both mice and humans, platelet CD40 mediates the formation of platelet-leukocyte aggregates and the release of chemokine (C-X-C motif) ligand 4. Leukocytes were also less prone to adhere to CD40-deficient thrombi. However, platelet CD40 was not involved in platelet aggregation. Activated platelets isolated from Cd40(-/-)Apoe(-/-) mice adhered less to the endothelium upon injection into Apoe(-/-) mice when compared with CD40-sufficient platelets. Furthermore, lack of CD40 on injected platelets led to reduced leukocyte recruitment to the carotid artery as assayed by intravital microscopy. This was accompanied by a decrease in endothelial vascular cell adhesion molecule-1, platelet endothelial cell adhesion molecule, VE-cadherin, and P-selectin expression. To investigate the effect of platelet CD40 in atherosclerosis, Apoe(-/-) mice received thrombin-activated Apoe(-/-) or Cd40(-/-)Apoe(-/-) platelets every 5 days for 12 weeks, starting at the age of 17 weeks, when atherosclerotic plaques had already formed. When compared with mice that received Apoe(-/-) platelets, those receiving Cd40(-/-)Apoe(-/-) platelets exhibited a > 2-fold reduction in atherosclerosis. Plaques of mice receiving CD40-deficient platelets were less advanced, contained less macrophages, neutrophils, and collagen, and displayed smaller lipid cores. Conclusions- Platelet CD40 plays a crucial role in inflammation by stimulating leukocyte activation and recruitment and activation of endothelial cells, thereby promoting atherosclerosis.
引用
收藏
页码:482 / 490
页数:9
相关论文
共 54 条
[1]   Immune-mediated and lipid-mediated platelet function in atherosclerosis [J].
Ahmadsei, Maiwand ;
Lievens, Dirk ;
Weber, Christian ;
von Hundelshausen, Philipp ;
Gerdes, Norbert .
CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (05) :438-448
[2]   Platelets express functional Toll-like receptor-4 [J].
Andonegui, G ;
Kerfoot, SM ;
McNagny, K ;
Ebbert, KVJ ;
Patel, KD ;
Kubes, P .
BLOOD, 2005, 106 (07) :2417-2423
[3]   CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism [J].
André, P ;
Prasad, KSS ;
Denis, CV ;
He, M ;
Papalia, JM ;
Hynes, RO ;
Phillips, DR ;
Wagner, DD .
NATURE MEDICINE, 2002, 8 (03) :247-252
[4]   Regulation of atherosclerotic plaque inflammation [J].
Back, M. ;
Weber, C. ;
Lutgens, E. .
JOURNAL OF INTERNAL MEDICINE, 2015, 278 (05) :462-482
[5]   Interleukin 1 Receptor 1 and Interleukin 1β Regulate Megakaryocyte Maturation, Platelet Activation, and Transcript Profile During Inflammation in Mice and Humans [J].
Beaulieu, Lea M. ;
Lin, Elaine ;
Mick, Eric ;
Koupenova, Milka ;
Weinberg, Ellen O. ;
Kramer, Carolyn D. ;
Genco, Caroline A. ;
Tanriverdi, Kahraman ;
Larson, Martin G. ;
Benjamin, Emelia J. ;
Freedman, Jane E. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34 (03) :552-564
[6]   A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma [J].
Bensinger, William ;
Maziarz, Richard T. ;
Jagannath, Sundar ;
Spencer, Andrew ;
Durrant, Simon ;
Becker, Pamela S. ;
Ewald, Brett ;
Bilic, Sanela ;
Rediske, John ;
Baeck, Johan ;
Stadtmauer, Edward A. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (01) :58-66
[7]   MECHANISMS OF DISEASE The Hemostatic System as a Modulator of Atherosclerosis [J].
Borissoff, Julian Ilcheff ;
Spronk, Henri M. H. ;
ten Cate, Hugo .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (18) :1746-1760
[8]   Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis -: Results from the Dallas Heart Study [J].
de Lemos, JA ;
Zirlik, A ;
Schönbeck, U ;
Varo, N ;
Murphy, SA ;
Khera, A ;
McGuire, DK ;
Stanek, G ;
Lo, HS ;
Nuzzo, R ;
Morrow, DA ;
Peshock, R ;
Libby, P .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (10) :2192-2196
[9]   Thrombosis as an intravascular effector of innate immunity [J].
Engelmann, Bernd ;
Massberg, Steffen .
NATURE REVIEWS IMMUNOLOGY, 2013, 13 (01) :34-45
[10]   Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia [J].
Garlichs, CD ;
John, S ;
Schmeisser, A ;
Eskafi, S ;
Stumpf, C ;
Karl, M ;
Goppelt-Struebe, M ;
Schmieder, R ;
Daniel, WG .
CIRCULATION, 2001, 104 (20) :2395-2400